Page 224 - Binder2
P. 224
It’s not just cheaper.
It’s immune-compatible, operationally efficient, and
globally accessible.
Oral GCase from plants is more than a replacement
therapy.
It’s the template for how enzyme therapies can evolve—
from infusion centers to kitchen counters, from annual six-
figure costs to scalable, shelf-stable capsules.
It doesn't just lower the barriers. It redefines where the
barriers are.
The Immunologic Edge
Oral enzyme delivery doesn’t just improve convenience—it
may actively reduce immune rejection.
Why?
Because oral delivery engages the immune system’s natural
tolerance pathways. When the gut sees a protein daily—
especially in a food-like matrix—it doesn’t mount an
attack. It learns to ignore it.
This has two effects:
1. Lower ADA formation, extending the effective
lifespan of the therapy
222
